Wom­en's health biotech nabs new an­timi­cro­bial treat­ment; Ovid finds part­ner for neu­ro­science col­lab­o­ra­tion

Daré Bio­science is on the move.

The biotech put out word ear­ly Wednes­day morn­ing that it’s signed a li­cens­ing agree­ment with Hen­nepin Life Sci­ences. Daré now has ex­clu­sive glob­al rights to de­vel­op and com­mer­cial­ize treat­ments de­liv­er­ing glyc­erol mono­lau­rate, or GML. GML is a new an­timi­cro­bial for a va­ri­ety of vagi­nal health con­di­tions — in­clud­ing bac­te­r­i­al, fun­gal and vi­ral in­fec­tions.

The biotech claims that due to its mech­a­nism of ac­tion, there is “lit­tle chance” of an­tibi­ot­ic re­sis­tance as a re­sult of this drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER